BioSpace News Archive

Our market experts have determined the current financial positions of the leading industry players in the report leveraging advanced analytical tools such as Porter’s Five Forces Analysis, SWOT analysis, and investment assessment.

Biologics Market was valued at USD 324.78 Billion in 2020 and is expected to reach a value of USD 749.62 Billion by 2028, and register a CAGR of 10.80% during the forecast period.

Microtome Market size was USD 134.2 Million in 2020 and is expected to register a revenue CAGR of 6.2% during the forecast period.

Sports Medicine Market size was USD 6.92 Billion in 2020 and is expected to register a revenue CAGR of 6.4% during the forecast period.

Surgical Devices Market size was USD 9.72 billion in 2020 and is expected to register a revenue CAGR of 9.6% during the forecast period.

The report consists of quantitative and qualitative research on the market performed by our market experts.

Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Lyo. Injection to its line of chemotherapy drugs.

Early predictions of the prognosis of glioblastoma (GBM)—one of most lethal cancers affecting the brain—could potentially improve the survival outcomes of patients.

Todos Medical, Ltd. (OTCQB: TOMDF) , a comprehensive medical diagnostics and related solutions company, today announced that majority-owned subsidiary 3CL Pharma will present final data from the phase 2 clinical trial of Tollovir™ in the treatment of hospitalized (severe and critical) COVID-19 patients at the Personalized Medicine World Conference (PMWC) on June 30th, 2022 at 1:30pm Pacific Time.

In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we’ve been informed by the company that in both the headline and first paragraph the name ‘Recofilstat’ should be ‘Rencofilstat’. Completed corrected text follows. Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Rencofilstat at 5th Global NASH Congress.